NEW YORK (GenomeWeb) – GeneCentric Diagnostics said in a document filed with the US Securities and Exchange Commission on Friday that it has raised $5 million in equity.

In an email to GenomeWeb Daily News, GeneCentric CEO Myla Lai-Goldman said the financing is the closing of the second tranche of the company's Series A financing round, and proceeds will go toward the continued development of its lead product called the Lung Subtype Platform. The company has raised $5.25 million to date, she said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.